SETD Inhibitors
SET domain-containing proteins (SETDs) are a diverse family of enzymes primarily known for their role as histone methyltransferases (HMTs), although some also possess non-histone methyltransferase activity. The SET domain itself is a conserved catalytic domain responsible for methylating specific lysine residues on histone tails, a key epigenetic modification that influences chromatin structure and gene expression. This methylation can lead to either transcriptional activation or repression, depending on the specific lysine residue targeted and the context of other epigenetic marks. For example, SETD1A and SETD1B are H3K4 methyltransferases, generally associated with active gene transcription, while SETD2 methylates H3K36, also linked to active transcription elongation. The dysregulation of SETD proteins is implicated in a broad spectrum of human diseases, including various cancers (e.g., acute myeloid leukemia, renal cell carcinoma, glioblastoma), developmental disorders, and neurological conditions.
For instance, mutations or altered expression of SETD2 are found in clear cell renal cell carcinoma, and SETD1A is implicated in certain developmental syndromes. The development of SETD inhibitors is an active area of research, with a focus on targeting specific SETD family members that are oncogenic drivers. Currently, most inhibitors are in the preclinical or early clinical development stages. Research has focused on developing small molecule inhibitors that can selectively block the catalytic activity of specific SETD proteins. For example, inhibitors targeting SETD2 and SETD1A/B are under investigation.
While no SETD inhibitors have been approved for clinical use yet, several compounds are showing promise in preclinical models. Classifications of inhibitors often relate to their selectivity for particular SETD proteins or their ability to target specific methylation marks. For instance, some inhibitors aim to be selective for SETD2 over other HMTs. Key research tools, such as specific antibodies against methylated histones or small molecules that modulate SETD activity, have been vital in understanding their roles. Significant challenges remain, including achieving high specificity for individual SETD proteins, as many share conserved catalytic domains, and understanding the complex, context-dependent roles of these enzymes in different cell types and disease states.
Overcoming potential toxicities arising from broad epigenetic disruption and developing predictive biomarkers for patient selection are also critical. Strategies involving combination therapies, potentially with other epigenetic drugs or targeted therapies, are being explored to enhance therapeutic outcomes and circumvent resistance mechanisms.
